Recent discussions on X about Rocket Pharmaceuticals (RCKT) have centered on the U.S. Food and Drug Administration's decision to lift the clinical hold on the company's pivotal Phase 2 trial for RP-A501, a gene therapy targeting Danon disease. Many users have expressed enthusiasm over the stock's significant surge, with some noting a pre-market increase of nearly 29% following the announcement. This development is seen as a critical milestone for the biotech firm, sparking conversations about its potential in the rare disease treatment space.
However, not all feedback has been uniformly positive, as some posts on X highlight lingering concerns about the therapy's long-term efficacy and the company's rapid cash burn rate. There are also mentions of a recent executive change, with the resignation of the CFO adding another layer of scrutiny to the firm's future plans. Despite these concerns, the predominant focus remains on the optimism surrounding the FDA's decision and the upcoming catalysts expected in 2026.
Note: This discussion summary was generated from an AI condensation of post data.
Rocket Pharmaceuticals Insider Trading Activity
Rocket Pharmaceuticals insiders have traded $RCKT stock on the open market 25 times in the past 6 months. Of those trades, 3 have been purchases and 22 have been sales.
Here’s a breakdown of recent trading of $RCKT stock by insiders over the last 6 months:
- GAURAV SHAH (CEO) has made 1 purchase buying 20,000 shares for an estimated $101,600 and 2 sales selling 5,874 shares for an estimated $38,160.
- KINNARI PATEL (See Remarks) has made 1 purchase buying 21,099 shares for an estimated $99,165 and 2 sales selling 2,176 shares for an estimated $14,142.
- JONATHAN DAVID SCHWARTZ (See Remarks) has made 0 purchases and 5 sales selling 16,029 shares for an estimated $56,746.
- MARTIN WILSON (General Counsel) has made 0 purchases and 5 sales selling 15,234 shares for an estimated $51,355.
- AARON ONDREY (Chief Financial Officer) has made 0 purchases and 2 sales selling 8,966 shares for an estimated $43,903.
- JOHN MILITELLO (See Remarks) has made 0 purchases and 6 sales selling 9,833 shares for an estimated $36,203.
- ELISABETH BJORK purchased 10,000 shares for an estimated $34,100
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Rocket Pharmaceuticals Hedge Fund Activity
We have seen 118 institutional investors add shares of Rocket Pharmaceuticals stock to their portfolio, and 160 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP removed 12,626,491 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $30,934,902
- WESTFIELD CAPITAL MANAGEMENT CO LP removed 4,820,701 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $11,810,717
- JANUS HENDERSON GROUP PLC removed 3,255,590 shares (-98.9%) from their portfolio in Q2 2025, for an estimated $7,976,195
- MAVERICK CAPITAL LTD added 3,164,595 shares (+60.9%) to their portfolio in Q2 2025, for an estimated $7,753,257
- MPM BIOIMPACT LLC added 2,284,816 shares (+141.2%) to their portfolio in Q2 2025, for an estimated $5,597,799
- NEWTYN MANAGEMENT, LLC added 2,000,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $4,900,000
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,943,853 shares (-63.9%) from their portfolio in Q2 2025, for an estimated $4,762,439
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Rocket Pharmaceuticals Analyst Ratings
Wall Street analysts have issued reports on $RCKT in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B of A Securities issued a "Buy" rating on 08/20/2025
- Chardan Capital issued a "Buy" rating on 08/20/2025
- Cantor Fitzgerald issued a "Overweight" rating on 08/08/2025
- Canaccord Genuity issued a "Buy" rating on 07/25/2025
- UBS issued a "Buy" rating on 06/17/2025
- BMO Capital issued a "Outperform" rating on 05/28/2025
- Scotiabank issued a "Sector Outperform" rating on 05/28/2025
To track analyst ratings and price targets for Rocket Pharmaceuticals, check out Quiver Quantitative's $RCKT forecast page.
Rocket Pharmaceuticals Price Targets
Multiple analysts have issued price targets for $RCKT recently. We have seen 14 analysts offer price targets for $RCKT in the last 6 months, with a median target of $10.0.
Here are some recent targets:
- Geulah Livshits from Chardan Capital set a target price of $11.0 on 08/20/2025
- Jason Zemansky from B of A Securities set a target price of $10.0 on 08/20/2025
- Josh Schimmer from Cantor Fitzgerald set a target price of $8.0 on 08/08/2025
- Whitney Ijem from Canaccord Genuity set a target price of $10.0 on 07/25/2025
- Colin Bristow from UBS set a target price of $5.0 on 06/17/2025
- Andrew Tsai from Jefferies set a target price of $2.5 on 05/28/2025
- Kostas Biliouris from BMO Capital set a target price of $8.0 on 05/28/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
